CLDX
NASDAQ
US
Celldex Therapeutics, Inc. - Common Stock
$31.06
▼ $-0.20
(-0.64%)
Vol 5.2M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.8B
ROE
-33.2%
Margin
-3446.9%
D/E
0.00
Beta
1.23
52W
$14–$31
Wall Street Consensus
22 analysts · Apr 20267
Strong Buy
12
Buy
2
Hold
1
Sell
0
Strong Sell
86.4%
Buy Rating
Price Chart
Similar Stocks
DAWN
Day One Biopharmaceuticals Inc
$956.9M
ADMA
ADMA Biologics Inc
P/E 20.7
$4.3B
RARE
Ultragenyx Pharmaceutical Inc
$2.2B
TYRA
Tyra Biosciences Inc
$1.4B
AGIO
Agios Pharmaceuticals Inc
$1.6B
SLNO
Soleno Therapeutics Inc
$2.5B
STOK
Stoke Therapeutics Inc
P/E 44.2
$1.8B
VRDN
Viridian Therapeutics Inc
$3.0B
CAPR
Capricor Therapeutics Inc
$1.6B
SION
Sionna Therapeutics Inc
$1.8B
About Celldex Therapeutics, Inc. - Common Stock
Celldex Therapeutics (CLDX) - біотехнологічна компанія, що розробляє імунотерапевтичні препарати для лікування різних видів раку. Вони зосереджені на розробці антитіл, які націлені на специфічні мішені на ракових клітинах, активуючи імунну систему для боротьби з хворобою. Компанія має перспективні клінічні дослідження, але знаходиться на етапі розробки, що робить її залежною від успіху цих досліджень.
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.03 | $-1.22 | $-0.19 |
| Sep 2025 | $-0.92 | $-1.01 | $-0.09 |
| Jun 2025 | $-0.87 | $-0.85 | +$0.02 |
| Mar 2025 | $-0.77 | $-0.81 | $-0.04 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -27.6% | -27.6% | -27.6% | -27.6% | -33.2% | -33.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -7753.4% | -3446.9% | -3446.9% | -3446.9% | -3446.9% | -3446.9% |
| Gross Margin | — | 17.6% | 17.6% | 17.6% | 17.6% | 17.6% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 19.67 | 19.67 | 19.67 | 19.67 | 13.01 | 13.01 |
Key Ratios
ROA (TTM)
-31.3%
P/S (TTM)
311.65
P/B
2.2
EPS (TTM)
$-3.38
CF/Share
$-2.58
Rev Growth 3Y
+14.7%
52W High
$30.50
52W Low
$14.40
$14.40
52-Week Range
$30.50
How does CLDX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CLDX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
311.7
▲
2325%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
2.2
▼
9%
below
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CLDX profitability vs Biotechnology peers
ROE
-33.2%
▲
51%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-3446.9%
▼
1102%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
17.7%
▼
78%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-31.3%
▲
33%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
CLDX financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
13.0
▲
193%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.2
▲
27%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CLDX fundamentals radar
CLDX
Peer median
Industry
CLDX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CLDX vs peers: key metrics
Latest News
No related news yet